Claims

1. Use of lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof in the manufacture of a medicament for the treatment of splanchnic vasodilatation in a patient with a liver condition.

2. The use of claim 1, wherein the liver condition is cirrhosis, acute liver failure, acute-on-chronic liver failure, hepatopulmonary syndrome, hepatorenal syndrome, or hepatic encephalopathy.

3. The use of any one of claims 1 to 2, wherein the liver condition is cirrhosis, in particular decompensated cirrhosis.

4. The use of any one of claims 1 to 3, wherein lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof is intended to be administered at a daily dose of from about 5 mg to about 1,200 mg.

5. The use according to any one of claims 1 to 4, wherein the deuterated form of lanifibranor is a compound of formula (I):



(I)

wherein at least one of the groups R_1 to R_7 is a deuterium (D) atom and the other groups R_1 to R_7 are hydrogen (H) atoms.

6. Use of a pharmaceutical composition comprising a pharmaceutically effective amount of lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof in the manufacture of a medicament for the treatment of splanchnic vasodilatation in a patient with a liver condition.

7. The use of claim 6, wherein the pharmaceutical composition is a solid dosage form, a semi-solid dosage form or a liquid dosage form, advantageously a solid dosage form.

8. The use of any one of claims 6 to 7, wherein the solid dosage form is a tablet, a capsule, a stick-pack, a sachet, a lozenge, a powder, a pill or a granule, advantageously a tablet, a capsule or a stick-pack.

9. The use of any one of claims 6 to 8, wherein the pharmaceutical composition comprises from 5 mg to 1,200 mg of lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof.

10. The use of claim 9, wherein the pharmaceutical composition comprises at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 85 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 150 mg, at least 200 mg, at least 250 mg, at least 300 mg, at least 350 mg, at least 400 mg, at least 450 mg, at least 500 mg, at least 550 mg, at least 600 mg, at least 650 mg, at least 700 mg, at least 750 mg, at least 800 mg, at least 850 mg, at least 900 mg, at least 950 mg, at least 1,000 mg, at least 1,050 mg, at least 1,100 mg, at least 1,150 mg, or 1,200 mg of lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof.

11. The use of any one of claims 6 to 10, wherein the pharmaceutical composition is an oral, parenteral or topical composition.